ACB Stock Analysis: Buy, Sell, or Hold?
ACB - Aurora Cannabis Inc. Common Shares
$2.85
-0.02 (-0.70%)
▼
5d:
-3.39%
30d:
-19.94%
90d:
-13.9%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When ACB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ACB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ACB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: ACB is currently trading at $2.85, which is considered oversold relative to its 30-day fair value range of $3.05 to $3.55. From a valuation perspective, the stock is trading at a discount (Forward PE: -475.0) compared to its historical average (43.0). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, ACB is in a downtrend. Immediate support is located at $2.73, while resistance sits at $3.51.
Market Sentiment: ACB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.23 (+118.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACB is in a downtrend. Immediate support is located at $2.73, while resistance sits at $3.51.
Market Sentiment: ACB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.23 (+118.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.05 -
$3.55
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding ACB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 118.5% below Wall St target ($6.23)
Trading Range Analysis
30-Day Trading Range
$3.05 -
$3.55
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.73
Resistance Level
$3.51
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-475.00
Wall Street Target
$6.23
(+118.5%)
Revenue Growth (YoY)
5.1%
Earnings Growth (YoY)
-94.7%
Profit Margin
-42.4%
PE vs Historical
-475.0 vs 43.0
CHEAP
Share & Embed Analysis
Last updated: June 24, 2026 5:10 AM ET
Data refreshes hourly during market hours. Next update: 6:10 AM
Data refreshes hourly during market hours. Next update: 6:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
Advanced ACB Option Strategies
Professional options setups generated by AI based on today's ACB price and gamma walls.
